Unidad de Investigación Clínica de Cáncer de Próstata

David Olmos Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext 2950)
dolmos@cnio.es

Investigadores

Pedro P. Lopez-Casas

Investigador Clínico I

Daniel Alameda
Elena Castro

Becarios Post-doctorales

Carlo Cattrini
Rebeca Lozano
David Martínez
María Isabel Pacheco

Técnicos de Laboratorio

Mónica Balsells
Eva María Casas
Ylenia Cendón
Jenniffer Patricia Condo
Teresa Garcés
Leticia Rivera
Alejandro Sanz
Francesca Maria Vitrone

Prostate cancer (PrCa) is one of the most heritable human cancers. Inherited mutations in several genes involved in DNA damage response and repair have been reported to predispose men to PrCa, including mutations in BRCA2. Seminal work from our Group has established that these mutations are an independent prognostic factor for the disease.

The Prostate Cancer Clinical Research Unit remains a major contributor to CNIO’s scientific productivity, with a total IF > 90 in 2019, and an accumulated IF > 500 since the Unit’s creation in 2012. These figures include 15 manuscripts led or co-led by the team in first-decile journals, and 3 major contributions to clinical practice included in the NCCN, EAU, ASCO, and/or ESMO PrCa management and treatment guidelines. Our associated CNIO-IBIMA CRU has consolidated as the biggest disease-specific CNIO clinical unit in numbers of CNIO sponsored studies and patients enrolled in these studies. The Unit has contributed significantly to major clinical trials in the field, such as SPARTAN or PROFOUND (both published in NEJM with D. Olmos as author), that led to the approvals of the novel anti-androgen apalutamide and the PARP inhibitor olaparib, respectively. In 2019, this Unit enrolled a record of 132 patients in prostate cancer trials.

Our Group continues to be successful in securing competitive national and international grants. 2019 was a record year in terms of funding: we received the ‘Excellence in Research’ CRIS Foundation Grant, the prestigious ‘Proyectos AECC Grant’, as well as 1 of the Top 3 AES-ISCIII research grants (both in scoring and financial support). Overall this positions our Unit as one of top performing units at CNIO, contributing significantly to the excellence profile of the institution.

Publicaciones

Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators, Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E (2020). HSD3B1 (1245A>C) Germline Variant and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone and Enzalutamide: Results From Two Prospective Studies. Ann Oncol 31, 1186-1197. Publicación CNIO.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ (2020). Apalutamide and Overall Survival in Prostate Cancer. Eur Urol (in press). Publicación CNIO.
Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E (2020). BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. Journal of Oncology (in press). Publicación CNIO.
Correa R , Navarro M , Lobato M , Otero A , Jerez I , Rico JM , Zapata I , Lupiañez Y , Medina JA, Olmos D, Gómez-Millán J (2020). Influence of the Technique and Comorbidities in Hypofractionated Radiotherapy for Prostate Cancer. Clin Transl Oncol 22, 311-318. Publicación CNIO.
Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E (2019). Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.. Eur Urol Oncol (in press). Publicación CNIO.
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR (2019). Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol 30, 1813-1820. Publicación CNIO.
Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D (2019). Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers 11, E1355. Publicación CNIO. Open Access
Lozano R, Almagro E, Castro E (2019). Relevance of radium-223 in hospital clinical practice from a medical oncologist point of view. Rev Esp Med Nucl Imagen Mol. 38, 106-111. Publicación CNIO.
Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U (2019). Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Eur Urol 75, 368-373. Publicación CNIO.
Naldaiz-Gastesi N, Goicoechea M, Aragón IM, Pérez-López V, Fuertes-Alvarez S, Herrera-Imbroda B, López de Munain A, de Luna-Diaz R, Baptista PM, Fernández MA, Lara MF, Izeta A (2019). Isolation and characterization of myogenic precursor cells from human cremaster muscle. Sci. Reports 9, 3454. Publicación CNIO. Open Access
Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E (2019). BRCA2 and Other DDR Genes in Prostate Cancer. Cancers 11, E352. Publicación CNIO. Open Access
Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D (2019). PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 37, 490-503. Publicación CNIO.
Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Scher HI, Terstappen LWMM, de Bono JS. (2018). Circulating Tumor Cell Increase as a Biomarker of Disease Progression in Metastatic Castration-Resistant Prostate Cancer Patients with Low Baseline CTC Counts.. Ann Oncol (in press). Publicación CNIO.
Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Scher HI, Terstappen LWMM, de Bono JS (2018). Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol 29, 1554-1560. Publicación CNIO.
Romero-Laorden N, Lozano R, Jayaram A, López-Campos F, Saez MI, Montesa A, Gutierrez-Pecharoman A, Villatoro R, Herrera B, Correa R, Rosero A, Pacheco MI, Garcés T, Cendón Y, Nombela MP, Van de Poll F, Grau G, Rivera L, López PP, Cruz JJ, Lorente D, Attard G, Castro E, Olmos D (2018). Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer 119, 1052-1059. Publicación CNIO.
Rodriguez-Vida A, Torregrosa MD, Pinto Á, Climent MÁ, Olmos D, Carles J (2018). Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. Clin Transl Oncol 20, 676-686. Publicación CNIO.
Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M (2018). SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol 20, 57-68. Publicación CNIO.
Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP (2018). Patient-derived models of abiraterone and enzalutamide resistant prostate cancer reveal sensitivity to ribosome-directed therapy. Eur Urol 74, 562-572. Publicación CNIO.
Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA (2018). Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118, 266-276. Publicación CNIO.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators (2018). Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. New Engl J Med 378, 1408-1418. Publicación CNIO.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS (2017). DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol 71, 417-425. Publicación CNIO.
Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH (2017). Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.. Ann Oncol 28, 1590-1596. Publicación CNIO.
García JL, Lozano R, Misiewicz-Krzeminska I, Fernández-Mateos J, Krzeminski P, Alfonso S, Marcos RA, García R, Gómez-Veiga F, Virseda Á, Herrero M, Olmos D, Cruz-Hernández JJ. (2017). A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.. Clin Transl Oncol 19, 1350-1357. Publicación CNIO.
Moynihan C, Bancroft EK, Mitra A, Ardern-Jones A, Castro E, Page EC, Eeles RA (2017). Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer.. Psycho-Oncol 26, 1987-1993. Publicación CNIO.
Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S (2017). The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer (in press). Publicación CNIO.
Romero-Laorden N, Castro E (2017). Inherited mutations in DNA repair genes and cancer risk.. Curr Prob Cancer 41, 251-264. Publicación CNIO.
Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A (2017). mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.. Nature 547, 109-113. Publicación CNIO.
Romero-Laorden N, Piñeiro-Yañez E, Gutierrez-Pecharroman A, Pacheco MI, Calvo E, Al-Shahrour F, Castro E, Olmos D (2017). Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.. Ann Oncol 28, 1158-1159. Publicación CNIO.
Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS (2016). Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.. Eur Urol 70, 985-992. Publicación CNIO.
Missiaglia E, Shepherd CJ, Aladowicz E, Olmos D, Selfe J, Pierron G, Delattre O, Walters Z, Shipley J (2016). MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.. Cancer Lett (in press). Publicación CNIO.
Mateo J, Olmos D, Dumez H, Poondru S, Samberg NL, Barr S, Van Tornout JM, Jie F, Sandhu S, Tan DS, Moreno V, LoRusso PM, Kaye SB, Schöffski P. (2016). A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.. Br J Cancer 114, 889-896. Publicación CNIO.
Castro E, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, Saunders E, Borley N, Keating D, Page EC, Saya S, Hazell S, Livni N, deSouza N, Neal D, Hamdy FC, Kumar P, Antoniou AC, Kote-Jarai Z; PROFILE Study Steering Committee, Eeles RA (2016). The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.. Oncologist 21, 716-722. Publicación CNIO.
Castro E, Mateo J, Olmos D, de Bono JS (2016). Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.. Cancer J 22, 353-356. Publicación CNIO.
Selfe J, Olmos D, Al-Saadi R, Thway K, Chisholm J, Kelsey A, Shipley J (2016). Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.. Pediatr Blood Cancer (in press). Publicación CNIO.
Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS (2015). Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.. J Clin Oncol 33, 1348-1355. Publicación CNIO.
Castro E, Goh Ch , Leongamornlert D , Saunders E, Tymrakiewicz M , Dadaev T , Govindasami K , Guy M , Ellis S , Frost D , Bancroft E , Cole T , Tischkowitz M , Kennedy MJ , Eason J , Brewer C , Gareth E, Davidson R , Eccles D , Porteous ME , Douglas F , Adlard J , Donaldson A , Antoniou AC , Kote-Jarai Z , Easton DF , Olmos D, Eeles R (2015). Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.. Eur Urol 68, 186-193. Publicación CNIO.
Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS (2015). Anti-tumour activity in RAS-driven tumours by blocking AKT and MEK.. Clin Cancer Res 21, 739-748. Publicación CNIO.
Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK (2015). A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med 13, 201. Publicación CNIO. Open Access
Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D7, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A (2015). New advances in genitourinary cancer: evidence gathered in 2014.. Cancer Metast Rev 34, 443-464. Publicación CNIO.
Castro E, Lozano R, Olmos D (2015). Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomakers?. Ann Oncol 26, 622-623. Publicación CNIO.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. (2015). Management of patients with advanced prostate cancer: Recommendations of the St.Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol 26, 1589-1604. Publicación CNIO.
Climent MÁ1, León-Mateos L2, González Del Alba A3, Pérez-Valderrama B4, Méndez-Vidal MJ5, Mellado B6, Arranz JÁ7, Sánchez-Hernández A8, Cassinello J9, Olmos D10, Carles J11. (2015). Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.. Crit Rev Oncol Hematol 96, 308-318. Publicación CNIO.
Rueda A, Olmos D, Vicioso L, Quero C, Gallego E, Pajares-Hachero BI, Mendiola M, Casanova M, Alvarez M, Provencio M, Alba E (2015). Role of vascular endothelial growth factor C in classical c.. Leuk Lymphoma 56, 1286-1294. Publicación CNIO.
Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, Eeles R, Kote-Jarai, UKGPCS, EMBRACE and IMPACT studies. (2015). High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.. Ann Oncol 26, 2293-2300. Publicación CNIO.